Abstract
RSV is a high priority for vaccine development because of its propensity to cause pneumonia and bronchiolitis in the infant and young child. Since RSV infection is likely to be a substantial contributor to otitis media, a vaccine could also decrease rates of this disease. No vaccine has yet been developed but it is hoped that the availability of an RSV infectious clone will make it possible to develop a live virus vaccine for the infant and young child. Subunit RSV vaccines are being developed for previously infected persons, i.e. in older children at high risk for RSV disease and the elderly. An effective RSV vaccine for the infant and young child could markedly decrease otitis media disease.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Aged
-
Antigens, Viral / genetics
-
Antigens, Viral / immunology
-
Child
-
Child, Preschool
-
Clinical Trials as Topic
-
Gene Deletion
-
Humans
-
Infant
-
Otitis Media / etiology
-
Otitis Media / prevention & control*
-
Otitis Media / virology
-
Pneumonia, Viral / etiology
-
Pneumonia, Viral / prevention & control
-
Recombinant Fusion Proteins / immunology
-
Respiratory Syncytial Virus Infections / complications
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus Vaccines*
-
Respiratory Syncytial Viruses / genetics
-
Respiratory Syncytial Viruses / immunology*
-
Respiratory Syncytial Viruses / physiology
-
Safety
-
Vaccination
-
Vaccines, Attenuated / immunology
-
Vaccines, DNA / immunology
-
Vaccines, Subunit / immunology
-
Viral Proteins / genetics
-
Viral Proteins / immunology
Substances
-
Antigens, Viral
-
Recombinant Fusion Proteins
-
Respiratory Syncytial Virus Vaccines
-
Vaccines, Attenuated
-
Vaccines, DNA
-
Vaccines, Subunit
-
Viral Proteins